Central Nervous System News and Research

RSS

Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks

Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd.

22 Sep 2011

Study reveals possible new treatment targets for diffuse intrinsic pontine gliomas

Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.

21 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

Nanoparticles have a detrimental effect on the fish brain

Scientists at the University of Plymouth have shown, for the first time in an animal, that nanoparticles have a detrimental effect on the brain and other parts of the central nervous system.

19 Sep 2011

Alkermes completes merger with Elan Drug Technologies

Alkermes plc and Elan Corporation, plc today announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011.

17 Sep 2011

Karolinska Institutet professor earns 2011 ECNP Neuropsychopharmacology Award

This year's ECNP Neuropsychopharmacology Award in Basic Science Research has been conferred upon Bertil Fredholm at the 24th Congress of the European College of Neuropsychopharmacology (ECNP) on 3-7 September 2011 in Paris, France.

16 Sep 2011

Scientists discover new type of spinal cord stem cell

A group led by a University of British Columbia and Vancouver Coastal Health scientist has discovered a type of spinal cord cell that could function as a stem cell, with the ability to regenerate portions of the central nervous system in people with spinal cord injuries, multiple sclerosis or amyotrophic lateral sclerosis.

16 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

JHUSON nursing research news

In a six-month, randomized controlled study of asthmatic children living with smokers reported in the Archives of Pediatrics and Adolescent Medicine, August 2011, Johns Hopkins University School of Nursing (JHUSON) professor and School of Medicine faculty member Arlene Butz, MSN, CPNP, ScD, and others found that regular use of indoor air cleaners can greatly reduce household air pollution and lower rates of children's daytime asthma symptoms.

12 Sep 2011

NASA selects nine projects to investigate space radiation's effect on human explorers

NASA is funding nine proposals from eight states to investigate space radiation's effect on human explorers. The proposals from researchers in California, Colorado, Florida, Georgia, Maryland, Massachusetts, New York and Texas have a total value of approximately $12 million.

12 Sep 2011

FDA panel votes 9-2 in favor of new blood thinner drug

A new stroke preventer from Bayer and Johnson & Johnson – Xarelto moved one step closer to U.S. approval, but questions remained about restrictions on labeling and the need for more studies.

9 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Possible link between mother's diet and risk of allergies in children

A possible link between what a mother eats during pregnancy and the risk of her child developing allergies has been identified in new research published in this month's The Journal of Physiology.

9 Sep 2011

Oxycodone no safer than codeine for breastfed infants: New study

Doctors have been prescribing codeine for postpartum pain management for many years, and, until recently, it was considered safe to breastfeed while taking the opioid. But the death of an infant exposed to codeine through breast milk has many health care providers questioning the safety of the drug when used by breastfeeding mothers.

7 Sep 2011

European Neurotech Investing & Partnering Summit to take place in Helsinki

The inaugural European Neurotech Investing & Partnering Summit takes place in Helsinki this week. It features keynotes on the state of the European neurotech industry, investor analysis, as well as company and research project presentations on next generation treatments emerging in the EU for unmet needs of brain and nervous system disorders like Alzheimer's, addiction, depression, schizophrenia, Parkinson's, Huntington's, stroke and more.

6 Sep 2011

Inhibiting the ability of immune cells to use fatty acids slows MS progression

In a paper published today in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model of multiple sclerosis.

3 Sep 2011

Bioness announces commercial release of NESS L300 Plus System

Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.

29 Aug 2011